Asuka Tsuya

Akita University — Japan

Medicine · Health Sciences

29h-index3.1kcitations166works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(96), Lung Cancer Research Studies(65), HER2/EGFR in Cancer Research(47), Colorectal Cancer Treatments and Studies(19), Lung Cancer Diagnosis and Treatment(18)

Publications166 total

Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025Open Access
Functional stability of the second mitotic spindle in blastomeres and its association with multinucleation repair
F&S Science·2025Open Access
Public assistance and survival equality in patients with <i>EGFR</i> mutation-positive lung cancer
Japanese Journal of Clinical Oncology·2024· 1 citedOpen Access
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1
Cancer Chemotherapy and Pharmacology·2024· 2 cited
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
JAMA Oncology·2023· 38 citedOpen Access
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
JTO Clinical and Research Reports·2023· 7 citedOpen Access
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for <i>EGFR</i> mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01)
Japanese Journal of Clinical Oncology·2023· 6 cited
Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2023Open Access
Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2023Open Access
Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Nobuyuki Yamamoto(41), Yukiko Nakamura(36), Haruyasu Murakami(36), Toshiaki Takahashi(36), Masahiro Endo(35), Tateaki Naito(33), Kyoichi Kaira(24), Akira Ono(23), Takehito Shukuya(21), Hirotsugu Kenmotsu(15), Satoshi Igawa(10), Takashi Nakajima(9), Hiroaki Akamatsu(8), Rieko Kaira(8), Kazuhiko Nakagawa(7), Haruhiko Kondo(7), Yasuhiro Koh(6), Akihiro Tamiya(6), Reiko Watanabe(5), Isamu Okamoto(5)